Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Share-based Compensation: 2019-2025

Historic Share-based Compensation for IDEAYA Biosciences (IDYA) over the last 7 years, with Sep 2025 value amounting to $12.2 million.

  • IDEAYA Biosciences' Share-based Compensation rose 32.58% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.8 million, marking a year-over-year increase of 45.74%. This contributed to the annual value of $34.7 million for FY2024, which is 87.93% up from last year.
  • IDEAYA Biosciences' Share-based Compensation amounted to $12.2 million in Q3 2025, which was up 2.94% from $11.9 million recorded in Q2 2025.
  • IDEAYA Biosciences' Share-based Compensation's 5-year high stood at $12.2 million during Q3 2025, with a 5-year trough of $1.9 million in Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $9.2 million (2024), whereas its average is $8.0 million.
  • Data for IDEAYA Biosciences' Share-based Compensation shows a peak YoY soared of 153.03% (in 2021) over the last 5 years.
  • Quarterly analysis of 5 years shows IDEAYA Biosciences' Share-based Compensation stood at $2.1 million in 2021, then surged by 44.14% to $3.0 million in 2022, then soared by 61.28% to $4.8 million in 2023, then surged by 97.69% to $9.5 million in 2024, then soared by 32.58% to $12.2 million in 2025.
  • Its Share-based Compensation stands at $12.2 million for Q3 2025, versus $11.9 million for Q2 2025 and $10.2 million for Q1 2025.